Food-specific serum IgG and symptom reduction with a personalized, unrestricted-calorie diet of six weeks in Irritable Bowel Syndrome (IBS).
Food-specific serum IgG and symptom reduction with a personalized, unrestricted-calorie diet of six weeks in Irritable Bowel Syndrome (IBS).
复制标题
肠易激综合症（IBS）的个性化，不受限制的热量饮食（IBS），食物特异性血清IgG和症状减轻。
DOI：
10.1186/s12986-020-00528-x
复制
发表时间：
2020-12-01
影响因子：
4.5
通讯作者：
Speciani AF
中科院分区：
文献类型：
--
作者：
Cappelletti M;Tognon E;Vona L;Basello K;Costanzi A;Speciani MC;Speciani AF
Irritable Bowel Syndrome (IBS) is a widespread disease with variable symptoms that have an important impact on the quality of life. Despite the prevalence of IBS, its etiology and pathophysiology are still to be fully understood, but immune response is known to be involved. In this study, we investigated the variation of two specific cytokines, B-cell activating factor (BAFF) and platelet-activating factor (PAF), the levels of food-specific IgG and the symptom severity, using Irritable Bowel Syndrome—Symptom Severity Score (IBS-SSS), following a personalized and unrestricted-calorie diet. We enrolled 30 subjects with diagnosis of IBS, according to Rome-IV criteria, whose inflammatory markers were measured at baseline and after 6 weeks of dietary intervention. The subjects were monitored in a general practice outpatient setting and nutritional advice was offered remotely via two telephone sessions with a nutritionist. BAFF and PAF values did not differ between baseline and end of study, both in compliant (C) and non-compliant (NC) subjects. IgG levels significantly decreased only in compliant subjects: 37.32 (23.24–93.67) IU/mL; 27.9 (7.56–93.96) IU/mL (p = 0.02) and in non-compliant went from 51.83 (13.17–113.1) IU/mL to 44.06 (4.96–255.4) IU/mL (p = 0.97, ns). IBS-SSS significantly decreased in both compliant subjects, from 245 (110–480) to 110 (0–140) (p < 0.0001), and non compliant subjects, from 250 (155–370) to 100 (7–220) (p < 0.0001). Comparing IBS-SSS between week 3 and week 6, only compliant subjects had a significant reduction, from 155 (50–355) to 110 (0–140) (p = 0.005), versus non-compliant, from 115 (35–315) to 100 (7–220) (p = 0.33, ns). These findings support the rapid efficacy and suitability of a personalized dietetic intervention with outside consultation in IBS. Trial registration: ClinicalTrials.gov ID NCT04348760 Registered April 15, 2020 (retrospectively registered) https://clinicaltrials.gov/show/NCT04348760
登录
查看更多内容
影响因子：
2.4
作者：
Ligaarden SC;Lydersen S;Farup PG
通讯作者：
Farup PG
DOI：
10.4049/jimmunol.1402527
发表时间：
2016-01-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Kang S;Keener AB;Jones SZ;Benschop RJ;Caro-Maldonado A;Rathmell JC;Clarke SH;Matsushima GK;Whitmire JK;Vilen BJ
通讯作者：
Vilen BJ
影响因子：
4.3
作者：
Makker, Jasbir;Chilimuri, Sridhar;Bella, Jonathan N.
通讯作者：
Bella, Jonathan N.
影响因子：
5.9
作者：
Piuri, Gabriele;Ferrazzi, Enrico;Speciani, Attilio Francesco
通讯作者：
Speciani, Attilio Francesco
影响因子：
3.4
作者：
Katsumata R;Ishii M;Lee S;Handa Y;Murao T;Fujita M;Matsumoto H;Otsuki T;Shiotani A
通讯作者：
Shiotani A